Should I buy or sell Omega Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omega Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OMGA shares. View OMGA analyst ratings or view top-rated stocks .

What is Omega Therapeutics' stock price target for 2024?

4 Wall Street analysts have issued 12 month price targets for Omega Therapeutics' stock. Their OMGA share price targets range from $7.00 to $12.00. On average, they anticipate the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 316.7% from the stock's current price. View analysts price targets for OMGA or view top-rated stocks among Wall Street analysts .

How have OMGA shares performed in 2024?

Omega Therapeutics' stock was trading at $3.01 at the beginning of 2024. Since then, OMGA shares have decreased by 20.3% and is now trading at $2.40. View the best growth stocks for 2024 here .

When is Omega Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our OMGA earnings forecast .

How were Omega Therapeutics' earnings last quarter?

Omega Therapeutics, Inc. (NASDAQ:OMGA) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.09. Omega Therapeutics had a negative net margin of 3,147.92% and a negative trailing twelve-month return on equity of 110.41%.

When did Omega Therapeutics IPO?

Omega Therapeutics (OMGA) raised $126 million in an IPO on Friday, July 30th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share.

How do I buy shares of Omega Therapeutics?

Shares of OMGA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OMGA

Omega Therapeutics (OMGA) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free OMGA Stock Alerts

$2.40

-0.02 (-0.83%)

(As of 04/19/2024 ET)

Compare

Today's Range: $2.35
▼
$2.45
50-Day Range: $2.40
▼
$4.33
52-Week Range: $1.30
▼
$10.09

Volume: 401,872 shs
Average Volume: 1.86 million shs
Market Capitalization: $132.36 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Get Omega Therapeutics alerts:

Omega Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 316.7% Upside
$10.00 Price Target
Short Interest: Bearish
19.78% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.37) to ($1.24) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.98 out of 5 stars

Medical Sector

575th out of 911 stocks

Biological Products, Except Diagnostic Industry

91st out of 150 stocks

3.5

Analyst's Opinion

Consensus Rating
Omega Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Omega Therapeutics has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
19.78% of the float of Omega Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Omega Therapeutics has a short interest ratio ("days to cover") of 5.3.
Change versus previous month
Short interest in Omega Therapeutics has recently increased by 4.12%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Omega Therapeutics does not currently pay a dividend.
Dividend Growth
Omega Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OMGA.

1.9

News and Social Media Coverage

News Sentiment
Omega Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
Search Interest
Only 8 people have searched for OMGA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
11 people have added Omega Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Omega Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
57.00% of the stock of Omega Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.47% of the stock of Omega Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Omega Therapeutics are expected to grow in the coming year, from ($1.37) to ($1.24) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Omega Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Omega Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Omega Therapeutics has a P/B Ratio of 2.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Omega Therapeutics Stock (NASDAQ:OMGA)

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

OMGA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OMGA Stock News Headlines

April 9, 2024 | globenewswire.com

Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control

March 31, 2024 | seekingalpha.com

Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 29, 2024 | finance.yahoo.com

We Think Omega Therapeutics (NASDAQ:OMGA) Needs To Drive Business Growth Carefully

March 29, 2024 | investorplace.com

OMGA Stock Earnings: Omega Therapeutics Beats EPS, Beats Revenue for Q4 2023

March 28, 2024 | globenewswire.com

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update

March 16, 2024 | finance.yahoo.com

OMGA Apr 2024 12.500 call

March 12, 2024 | markets.businessinsider.com

Intrommune Therapeutics Strengthens Board of Directors with Appointments of Dr. Jonathan Rich and Hem Pandya

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 6, 2024 | globenewswire.com

Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024

January 26, 2024 | benzinga.com

How Is The Market Feeling About Omega Therapeutics?

January 16, 2024 | seekingalpha.com

Omega Therapeutics: The Next Weight Loss Drug Runner

January 6, 2024 | morningstar.com

Omega Therapeutics Inc OMGA

January 5, 2024 | finance.yahoo.com

Novo Nordisk (NVO) Up on $1.1B Research Deals With 2 Biotechs

January 5, 2024 | finance.yahoo.com

Omega (OMGA) Up 95% on Obesity Drug Deal With Novo Nordisk

January 4, 2024 | msn.com

Omega (NASDAQ:OMGA) Skyrockets After Research Deal With Novo Nordisk

January 4, 2024 | realmoney.thestreet.com

Omega collaboration with Novo Nordisk 'validation' of OEG platform, says Wedbush

January 4, 2024 | fool.com

Why Novo Nordisk Stock Crushed the Market Today

January 4, 2024 | ca.finance.yahoo.com

OMGA Feb 2024 2.500 call

January 4, 2024 | markets.businessinsider.com

Famed Obesity Drug Maker Novo Nordisk Inks Collaborations For Cardiometabolic Diseases

January 4, 2024 | finance.yahoo.com

Novo Nordisk enters research partnerships with biotech firms

January 4, 2024 | finance.yahoo.com

Novo Nordisk, The Weight-Loss Kingpin, Breaks Out After Inking Two New Deals In Obesity

January 4, 2024 | investorplace.com

Why Is Omega Therapeutics (OMGA) Stock Up 111% Today?

January 4, 2024 | marketwatch.com

Omega Therapeutics Stock Surges 99% Following Pact with Novo Nordisk to Treat obesity

January 4, 2024 | msn.com

Novo Nordisk signs research deals on cardiometabolic diseases

January 4, 2024 | markets.businessinsider.com

Novo Nordisk Enters Collaboration Agreements With Omega And Cellarity

January 2, 2024 | finance.yahoo.com

Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

See More Headlines

Receive OMGA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omega Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:OMGA
CUSIP: N/A
CIK: 1850838
Web: www.omegatherapeutics.com
Phone: 617-949-4360
Fax: N/A
Employees: 116
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $12.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +316.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.81)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-97,430,000.00
Net Margins: -3,147.92%
Pretax Margin: -3,148.93%
Return on Equity: -110.41%
Return on Assets: -48.26%

Debt

Debt-to-Equity Ratio: 0.26
Current Ratio: 3.35
Quick Ratio: 3.35

Sales & Book Value

Annual Sales: $3.09 million
Price / Sales: 42.83
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.05 per share
Price / Book: 2.29

Miscellaneous

Outstanding Shares: 55,150,000
Free Float: 23,717,000
Market Cap: $132.36 million
Optionable: Optionable
Beta: 1.83

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Mahesh Karande (Age 50)
President, CEO & Board Director
Comp: $812.88k
Ms. Ling Zeng Esq. (Age 55)
J.D., Chief Legal & Administrative Officer and Secretary
Comp: $519.36k
Dr. Yan Moore M.D. (Age 57)
Chief Medical Officer
Comp: $1.14M
Mr. Joshua Reed M.B.A. (Age 50)
Chief Financial Officer
Dr. Sivakesava Sakhamuri Ph.D.
Senior VP and Head of Technical Operations & Quality
Dr. Thomas McCauley (Age 55)
Chief Scientific Officer
Comp: $588.5k
Mr. Anthony Mullin
Chief People Officer
Mr. Charles O'Donnell Ph.D.
VP and Head of Computational Genomics & Data Sciences

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OMGA Stock Analysis - Frequently Asked Questions

Should I buy or sell Omega Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omega Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OMGA shares.
View OMGA analyst ratings or view top-rated stocks.
What is Omega Therapeutics' stock price target for 2024?: 4 Wall Street analysts have issued 12 month price targets for Omega Therapeutics' stock. Their OMGA share price targets range from $7.00 to $12.00. On average, they anticipate the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 316.7% from the stock's current price.
View analysts price targets for OMGA or view top-rated stocks among Wall Street analysts.
How have OMGA shares performed in 2024?: Omega Therapeutics' stock was trading at $3.01 at the beginning of 2024. Since then, OMGA shares have decreased by 20.3% and is now trading at $2.40.
View the best growth stocks for 2024 here.
When is Omega Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our OMGA earnings forecast.

How were Omega Therapeutics' earnings last quarter?: Omega Therapeutics, Inc. (NASDAQ:OMGA) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.09. Omega Therapeutics had a negative net margin of 3,147.92% and a negative trailing twelve-month return on equity of 110.41%.
When did Omega Therapeutics IPO?: Omega Therapeutics (OMGA) raised $126 million in an IPO on Friday, July 30th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share.
How do I buy shares of Omega Therapeutics?: Shares of OMGA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OMGA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Omega Therapeutics (OMGA) Stock Price, News & Analysis

Omega Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Omega Therapeutics Stock (NASDAQ:OMGA)

OMGA Stock Price History

OMGA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

OMGA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™